BRAF Mutant Metastatic Melanoma Market Evolving at a Rapid Pace, Estimates DelveInsight | Key Companies Active in the Domain - Merck Sharp & Dohme, Eisai, Iovance Biotherapeutics, Genentech, Amgen, AstraZeneca, Pfizer, and Others

Rhea-AI Summary

The BRAF mutant metastatic melanoma market is poised for growth driven by enhanced diagnostic methods and increased healthcare spending globally. According to DelveInsight's report, the market is projected to expand significantly from 2019 to 2032, with a focus on the 7MM regions including the US and several EU countries. BRAF mutations are prevalent in approximately 50% of melanoma cases, with the V600E mutation being the most common. Leading companies such as Merck Sharp & Dohme and AstraZeneca are developing novel therapies, and the pipeline includes over 15 emerging treatments currently in mid-phase trials. While the market outlook is optimistic, challenges include therapy discontinuations and high treatment costs.

Positive

• Projected significant growth in BRAF mutant metastatic melanoma market during 2019-2032.
• Presence of multiple emerging therapies in clinical trials, potentially enhancing treatment options.
• Increased healthcare spending and improved diagnosis methodologies are expected to drive market expansion.

Negative

• Therapy failures and discontinuations may hinder market growth.
• Unaffordable pricing and reimbursement issues could limit patient access.
• Market growth may be affected by unreported and undiagnosed cases of melanoma.

The dynamics of the BRAF mutant metastatic melanoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world.

LAS VEGAS, April 13, 2023 /PRNewswire/ -- DelveInsight's BRAF Mutant Metastatic Melanoma Market Insights report includes a comprehensive understanding of current treatment practices, BRAF mutant metastatic melanoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the BRAF Mutant Metastatic Melanoma Market Report

• As per DelveInsight analysis, the BRAF BRAF mutant metastatic melanoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to The Cancer Genome Atlas Network, the BRAF mutation occurs in approximately 50% of cutaneous melanoma and the most common being the V600E (valine to glutamic acid; 70–88%). 
• Leading BRAF mutant metastatic melanoma companies such as Merck Sharp & Dohme, Eisai, Iovance Biotherapeutics, Checkmate Pharmaceuticals, Highlight Therapeutics, Aivita Biomedical, Inc., Bayer, Taiga Biotechnologies, Inc., Genentech, Inc., BioMed Valley Discoveries, Inc, Amgen, AstraZeneca, Seagen Inc., Bristol-Myers Squibb, Pfizer, Tesaro, Inc., MedImmune LLC, and others are developing novel BRAF mutant metastatic melanoma drugs that can be available in the BRAF mutant metastatic melanoma market in the coming years.
• Some key therapies for BRAF mutant metastatic melanoma treatment include LENVIMA (lenvatinib), LN-144, Vidutolimod (CMP-001), BO-112, AV-MEL-1, Tremelimumab + MEDI3617, Olaparib, BAY2666605, TBX-3400, Ipilimumab + Axitinib, Atezolizumab, BVD-523, T-Vec, Selumetinib, SGN-BB228, Nivolumab, Crizotinib, Niraparib, MEDI0562, and others.
• The emerging BRAF mutant metastatic melanoma therapies are in the mid-phase of their clinical trials and are awaiting a launch to make the pipeline robust.

Discover which therapies are expected to grab the major BRAF mutant metastatic melanoma market share @ BRAF Mutant Metastatic Melanoma Market Report

BRAF Mutant Metastatic Melanoma Overview

Melanoma is a type of skin cancer that develops from melanin cells in the upper layer of the skin (epidermis) or similar cells found in moles (nevi). This type of skin cancer can send roots into deeper layers of the skin, and some of these microscopic roots can spread (metastasize), causing new tumor growths in vital organs. The most common driver in melanoma is mutant BRAF, which is found in 40-50% of patients with metastatic disease. BRAF mutations are found in other cancers, such as colon cancer, papillary thyroid cancer, and serous ovarian cancer, but at a much lower frequency than in melanoma.

Almost half of all patients with metastatic disease have BRAF mutations. The most common mutation, the V600E missense mutation, has been shown in clinical trials to be responsive to BRAF inhibitors like vemurafenib and dabrafenib. Other V600 BRAF mutations, such as V600K, have been shown to respond to BRAF inhibitors, while MEK inhibitors are effective in a subset of non-V600 mutations.

BRAF Mutant Metastatic Melanoma Epidemiology Segmentation

The BRAF mutant metastatic melanoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Melanoma incident cases 
• Melanoma type-specific cases 
• Melanoma stage-specific incident cases
• Melanoma mutation-specific  (BRAF, MEK) incident cases 
• Mutant metastatic melanoma age-specific incident cases
• Total treated cases of BRAF mutant metastatic melanoma

Download the report to understand which factors are driving BRAF mutant metastatic melanoma epidemiology trends @ BRAF Mutant Metastatic Melanoma Epidemiological Insights

BRAF Mutant Metastatic Melanoma Treatment Market 

Melanoma treatment focuses on extending survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky disease sites to provide comfort. Melanoma treatment options include immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. Surgery, on the other hand, is considered an option in some cases.

Immunotherapy breakthroughs have resulted in significant progress in treating patients with advanced melanoma. Immunotherapy uses medicines to stimulate a patient's immune system to destroy cancer cells. Immunotherapies improve the body's ability to fight melanoma and other cancers by using synthetic versions of natural immune system proteins or by releasing tumor-attacking cells. When used alone or in combination, these therapies are effective.

Chemotherapy is no longer a first-line therapy because immunotherapies and targeted therapies produce far superior results. It is typically used when targeted therapies and checkpoint blockade therapies have failed, and it is occasionally used in conjunction with these other therapies. Radiation is rarely used to treat primary melanoma tumors. Still, it may be used to shrink tumors, reduce pain, and improve comfort and mobility in melanomas that have spread to the brain or other distant sites.

While there are more melanoma treatment options are available today than ever, even more, new approaches are being investigated. Researchers are working to refine therapeutic combinations and strategies to improve outcomes, building on today's strong forward momentum in understanding and treating melanoma. Advanced melanoma may be transformed from a fatal disease to a chronic, manageable, and even curable condition.

To know more about BRAF mutant metastatic melanoma treatment, visit @ BRAF Mutant Metastatic Melanoma Treatment Drugs 

Key BRAF Mutant Metastatic Melanoma Therapies and Companies

• LENVIMA (lenvatinib): Merck Sharp & Dohme/Eisai
• LN-144: Iovance Biotherapeutics
• Vidutolimod (CMP-001): Checkmate Pharmaceuticals
• BO-112: Highlight Therapeutics
• AV-MEL-1: Aivita Biomedical, Inc.
• Tremelimumab + MEDI3617: MedImmune LLC
• Olaparib: AstraZeneca
• BAY2666605: Bayer
• TBX-3400: Taiga Biotechnologies, Inc.
• Ipilimumab + Axitinib: Pfizer
• Atezolizumab: Genentech, Inc.
• BVD-523: BioMed Valley Discoveries, Inc
• T-Vec: Amgen
• Selumetinib: AstraZeneca
• SGN-BB228: Seagen Inc.
• Nivolumab: Bristol-Myers Squibb
• Crizotinib: Pfizer
• Niraparib: Tesaro, Inc.
• MEDI0562: MedImmune LLC

Learn more about the FDA-approved drugs for BRAF mutant metastatic melanoma @ Drugs for BRAF Mutant Metastatic Melanoma Treatment 

BRAF Mutant Metastatic Melanoma Market Dynamics

The BRAF mutant metastatic melanoma market dynamics are expected to change in the coming years. Drug combination therapy may result in more effective disease control. The efficacy of available drug classes, either as monotherapy or in combination, propels the BRAF mutant metastatic melanoma market growth. In addition, the introduction of novel drugs for neo-adjuvant therapy and a new class of therapeutic drugs to treat BRAF mutant metastatic melanoma and the BRAF mutant metastatic melanoma market will provide hope to melanoma patients as a therapeutic option and may have a significant positive impact on the BRAF mutant metastatic melanoma market. 

Furthermore, the BRAF mutant metastatic melanoma pipeline is very robust; many potential therapies are being investigated for the treatment of BRAF mutant metastatic melanoma, and it is safe to predict that the treatment space will significantly impact the BRAF mutant metastatic melanoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the BRAF mutant metastatic melanoma market in the 7MM.

However, several factors are impeding the growth of the BRAF mutant metastatic melanoma market. Melanoma is associated with a number of comorbidities and risk factors, including skin necrosis, pain on the skin sore, and lymphoedema, a condition in which the patient's lymph nodes rupture and fluid accumulates in the limbs. Furthermore, the BRAF mutant metastatic melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the BRAF mutant metastatic melanoma market growth.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year	2019
Key BRAF Mutant Metastatic Melanoma Companies	Merck Sharp & Dohme, Eisai, Iovance Biotherapeutics, Checkmate Pharmaceuticals, Highlight Therapeutics, Aivita Biomedical, Inc., Bayer, Taiga Biotechnologies, Inc., Genentech, Inc., BioMed Valley Discoveries, Inc, Amgen, AstraZeneca, Seagen Inc., Bristol-Myers Squibb, Pfizer, Tesaro, Inc., MedImmune LLC, and others
Key BRAF Mutant Metastatic Melanoma Therapies	LENVIMA (lenvatinib), LN-144, Vidutolimod (CMP-001), BO-112, AV-MEL-1, Tremelimumab + MEDI3617, Olaparib, BAY2666605, TBX-3400, Ipilimumab + Axitinib, Atezolizumab, BVD-523, T-Vec, Selumetinib, SGN-BB228, Nivolumab, Crizotinib, Niraparib, MEDI0562, and others

 

Scope of the BRAF Mutant Metastatic Melanoma Market Report

• Therapeutic Assessment: BRAF Mutant Metastatic Melanoma current marketed and emerging therapies
• BRAF Mutant Metastatic Melanoma Market Dynamics: Attribute Analysis of Emerging BRAF Mutant Metastatic Melanoma Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, BRAF Mutant Metastatic Melanoma Market Access and Reimbursement

Discover more about BRAF mutant metastatic melanoma drugs in development @ BRAF Mutant Metastatic Melanoma Clinical Trials

Table of Contents

1.	BRAF Mutant Metastatic Melanoma Market Key Insights
2.	BRAF Mutant Metastatic Melanoma Market Report Introduction
3.	BRAF Mutant Metastatic Melanoma Market Overview at a Glance
4.	BRAF Mutant Metastatic Melanoma Market Executive Summary
5.	Disease Background and Overview
6.	BRAF Mutant Metastatic Melanoma Treatment and Management
7.	BRAF Mutant Metastatic Melanoma Epidemiology and Patient Population
8.	Patient Journey
9.	BRAF Mutant Metastatic Melanoma Marketed Drugs
10.	BRAF Mutant Metastatic Melanoma Emerging Drugs
11.	Seven Major BRAF Mutant Metastatic Melanoma Market Analysis
12.	BRAF Mutant Metastatic Melanoma Market Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	BRAF Mutant Metastatic Melanoma Market Drivers
16.	BRAF Mutant Metastatic Melanoma Market Barriers
17.	Unmet Needs
18.	SWOT Analysis
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

 

Related Reports

BRAF Mutant Metastatic Melanoma Epidemiology Forecast

BRAF Mutant Metastatic Melanoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted BRAF mutant metastatic melanoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

BRAF Mutant Metastatic Melanoma Pipeline

BRAF Mutant Metastatic Melanoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key BRAF mutant metastatic melanoma companies, including Iovance BioTherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, among others.

Melanoma Market

Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key melanoma companies, including Immunocore Ltd, Novartis, Eli Lilly and Company, Apexigen, Inc., NovoCure Ltd., among others.

Melanoma Pipeline

Melanoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including Immunocore Ltd, Novartis, Eli Lilly and Company, Apexigen, Inc., NovoCure Ltd., among others.

Metastatic Melanoma Market

Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies, including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.

Metastatic Cutaneous Melanoma Market

Metastatic Cutaneous Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic cutaneous melanoma companies, including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.com/news-releases/braf-mutant-metastatic-melanoma-market-evolving-at-a-rapid-pace-estimates-delveinsight--key-companies-active-in-the-domain---merck-sharp--dohme-eisai-iovance-biotherapeutics-genentech-amgen-astrazeneca-pfizer-and-others-301796498.html

SOURCE DelveInsight Business Research, LLP

FAQ

What is the expected growth rate of the BRAF mutant metastatic melanoma market?

The BRAF mutant metastatic melanoma market is expected to grow significantly during the study period from 2019 to 2032.

Which companies are involved in developing therapies for BRAF mutant metastatic melanoma?

Key companies include Merck Sharp & Dohme, AstraZeneca, Iovance Biotherapeutics, and Genentech.

What are the common BRAF mutations found in melanoma?

The most common BRAF mutation is V600E, occurring in approximately 70-88% of cases.

What challenges does the BRAF mutant metastatic melanoma market face?

Challenges include therapy discontinuations, high treatment costs, and unreported cases of melanoma.

What is the timeline for emerging therapies for BRAF mutant metastatic melanoma?

Several emerging therapies are currently in mid-phase clinical trials and are anticipated to be available in the coming years.